Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;7(6):1119-1121.
doi: 10.3892/mco.2017.1432. Epub 2017 Sep 29.

MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development

John M Yavorski  1 , George Blanck  1   2
Affiliations

MHC class II associated stomach cancer mutations correlate with lack of subsequent tumor development

John M Yavorski et al. Mol Clin Oncol. 2017 Dec.

Abstract

The role of tumor cell expression of major histocompatibility class II (MHCII) has been controversial, with evidence indicating that tumor cell expression of MHCII may lead to an anti-tumor immune response and to tumor cell apoptosis and that MHCII has pro-tumorigenic functions. The cancer genome atlas (TCGA) indicates numerous deleterious mutations for the highly specific, MHCII transcriptional activation proteins, RFX5, RFXAP, RFXANK and CIITA. Also, mutations in the non-polymorphic, human leukocyte antigen (HLA)-DRA gene, which encodes the heavy chain for the most prominent human MHCII molecule, HLA-DR, are common. For many, if not most TCGA cancer datasets, the MHCII specific mutations do not associate with clinical outcomes. However, stomach carcinoma represents an exception, where the data indicate that MHCII-specific mutations are associated with a more favorable outcome. These data raise the question of whether stomach cancer mutations represent effective haploinsufficiency or whether mutations that are associated with a favorable outcome occur with other stomach cancer molecular features that limit the function of the two alleles that represent these MHCII-related proteins.

Keywords: HLA-DR; interferon-γ induction; major histocompatibility class II proteins; prognosis; solid tumor; stomach cancer.

PubMed Disclaimer

References

    1. Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G. Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J Immunol. 1996;156:2495–2502. - PubMed
    1. Blanck G. Components of the IFN-gamma signaling pathway in tumorigenesis. Arch Immunol Ther Exp (Warsz) 2002;50:151–158. - PubMed
    1. Xi H, Eason DD, Ghosh D, Dovhey S, Wright KL, Blanck G. Co-occupancy of the interferon regulatory element of the class II transactivator (CIITA) type IV promoter by interferon regulatory factors 1 and 2. Oncogene. 1999;18:5889–5903. doi: 10.1038/sj.onc.1202969. - DOI - PubMed
    1. Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blanck G. Evidence for retinoblastoma protein (RB) dependent and independent IFN-gamma responses: RB coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene. 1994;9:1015–1019. - PubMed
    1. Lu Y, Tschickardt ME, Schmidt BJ, Blanck G. IFN-gamma inducibility of class II transactivator is specifically lacking in human tumour lines: Relevance to retinoblastoma protein rescue of IFN-gamma inducibility of the HLA class II genes. Immunol Cell Biol. 1997;75:325–332. doi: 10.1038/icb.1997.50. - DOI - PubMed